Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. | Bo et al. Critical Care 2011 15 R58 http ccforum.eom content 15 1 R58 KS CRITICAL CARE RESEARCH Open Access Granulocyte-colony stimulating factor G-CSF and granulocyte-macrophage colony stimulating factor GM-CSF for sepsis a meta-analysis Lulong Bo Fei Wang Jiali Zhu Jinbao Li Xiaoming Deng Abstract Introduction To investigate the effects of G-CSF or GM-CSF therapy in non-neutropenic patients with sepsis. Methods A systematic literature search of Medline Embase and Cochrane Central Register of Controlled Trials was conducted using specific search terms. A manual review of references was also performed. Eligible studies were randomized control trials RCTs that compared granulocyte-colony stimulating factor G-CSF or granulocytemacrophage colony stimulating factor GM-CSF therapy with placebo for the treatment of sepsis in adults. Main outcome measures were all-cause mortality at 14 days and 28 days after initiation of G-CSF or GM-CSF therapy inhospital mortality reversal rate from infection and adverse events. Results Twelve RCTs with 2 380 patients were identified. In regard to 14-day mortality a total of 9 death events occurred among 71 patients 12.7 in the treatment group compared with 13 events among 67 patients 19.4 in the placebo groups. Meta-analysis showed there was no significant difference in 28-day mortality when G-CSF or GM-CSF were compared with placebo relative risks RR 0.93 95 confidence interval CI 0.79 to 1.11 P 0.44 P for heterogeneity 0.31 I2 15 . Compared with placebo G-CSF or GM-CSF therapy did not significantly reduce in-hospital mortality RR 0.97 95 CI 0.69 to 1.36 P 0.86 P for heterogeneity 0.80 I2 0 . However G-CSF or GM-CSF therapy significantly increased the reversal rate from infection RR 1.34 95 CI 1.11 to 1.62 P 0.002 P for heterogeneity 0.47 I2 0 . No significant difference was observed in adverse events between groups RR 0.93 95 CI 0.70 to 1.23 P 0.62 P for heterogeneity 0.03 I2 58 . Sensitivity analysis by excluding one trial did not .
